Evidence of cartilaginous benefit of treatment with infliximab in rheumatoid arthritis using measurement of serum COMP

Japanese Journal of Clinical Immunology

Volumn 30, Issue 1, 2007, Pages 41-47

  Yamamoto, Motohisa ^a   Takahashi, Hiroki ^a   Ohara, Mikiko ^a   Suzuki, Chisako ^a   Naishiro, Yasuyoshi ^a   Yamamoto, Hiroyuki ^a   Shinomura, Yasuhisa ^a   Imai, Kohzoh ^b  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cartilage oligomeric matrix protein (COMP); Infliximab; Methotrexate; Rheumatoid arthritis; Sharp score

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; CARTILAGE MATRIX PROTEIN; GLYCOPROTEIN; INFLIXIMAB; MONOCLONAL ANTIBODY; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD; CARTILAGE; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; RADIOGRAPHY; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CARTILAGE; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED;

EID: 34247895649     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.30.41     Document Type: Article

References (28)

1. American College of Rheumatology Subcommittee on Rheumatoid arthritis Guidelines: Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 46: 328–346, 2002.
2. Clair EW, et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 50: 3432–3443, 2004.
3. Klareskog L, et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double blind randomized controlled trial. Lancet 363: 675–681, 2004.
4. Neidhart M, et al.: Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 36: 1151–1160, 1997.
5. Garnero P, et al.: Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: Rekations with disease activity and joint damage. Ann Rheum Dis 60: 619–626, 2001.
6. Senolt L, et al.: Increased pentosidine, an advanced glycation end product, in serum and synovial luid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein. Ann Rheum Dis 64: 886–890, 2005.
7. Zaia J, et al.: Post-translational modifications in cartilage oligomeric matrix protein; characterization of the N-linked oligosaccharides by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. J Biol Chem 272: 14120–14126, 1997.
8. Arnett FC, et al.: The American Rheumatism Association 1987 revised criteria for the classiication of rheumatoid arthritis. Arthritis Rheum 31: 315–324, 1988.
9. van der Heijde DM: Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 10: 435–453, 1996.
10. Oldberg A: COMP is structurally related to the thrombospondins. JBiolChem 267: 22346–22350, 1992.
11. Hedbom E, et al.: Cartilage matrix proteins. An acidic origomeric protein (COMP) detected only in cartilage. JBiolChem 267: 6132–6136, 1992.
12. Di Cesare PE, et al.: Expression of cartilage oligomeric matrix protein by human synovium. FEBS Lett 412: 249–252, 1997.
13. Ikegawa S, et al.: Novel and recurrent COMP (cartilage oligomeric matrix protein) mutations in pseudoachondroplasia and multiple epiphyseal dysplasia. Hum Genet 103: 633–638, 1998.
14. Saxne T, Heinegard D: Cartilage oligomeric matrix protein: A novel marker of cartilage turnover detectable in synovial luid and blood. Br J Rheumatol 31: 583–591, 1992.
15. Shimada K, et al.: Serum cartilage origomeric matrix protein (COMP) concentration as a predicting marker for joint destruction in the early rheumatoid arthritis (RA) patients. Mod Rheumatol 15: S222, 2005.
16. Jordan JM: Update on cartilage oligomeric matrix protein as a marker of osteoarthritis. J Rheumatol 32: 1145–1147, 2005.
17. Jordan JM, et al.: Ethnic and sex diferences in serum levels of cartilage ologomeric matrix protein: The Johnston County Osteoarthritis Project. Arthritis Rheum 48: 675–681, 2003.
18. Neidhart M, et al.: Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthritis Cartilage 8: 222–229, 2000.
19. Vilim V, et al.: Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 10: 707–713, 2002.
20. Sharif M, et al.: Sugestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over ive years. Arthritis Rheum 50: 2479–2488, 2004.
21. Farina G, et al.: Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts. Matrix Biol 25: 213–222, 2006.
22. Skoumal M, Kolarz G, Klingler A.: Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scand J Rheumatol 32: 156–161, 2003.
23. Lindqvist E, et al.: Prognostic laboratory makers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 64: 196–201, 2005.
24. Wislowska M, Jablońska B.: Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis. Clin Rheumatol 24: 278–284, 2005.
25. Crnkic M, et al.: Serum cartilage origomeric matrix protein (COMP) decreased in rheumatoid arthritis patients treated with inliximab or etanercept. Arthritis Res Ther 5: R181–R185, 2003.
26. Lequerre T, et al.: Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients and unable to predict their responses to infliximab. Rheumatology (Oxford) 2006 Aug 9; [Epub ahead of print]
27. Miyasaka N, Takeuchi T, Eguchi K: Official Japanese guidelines for the use of inliximab for rheumatoid arthritis. Mod Rheumatol 15: 4–8, 2005.
28. Roux-Lombard P, et al.: Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: Relationship to radiological progression and inlammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology (Oxford) 40: 544–551, 2001.